Osteoporosis International

, Volume 23, Issue 10, pp 2527–2534 | Cite as

Hip fracture incidence is decreasing in the high incidence area of Oslo, Norway

  • R. Ø. StøenEmail author
  • L. Nordsletten
  • H. E. Meyer
  • J. F. Frihagen
  • J. A. Falch
  • C. M. Lofthus
Original Article



This study reports a significant decrease in age-adjusted incidence rates of hip fracture for women in Oslo, Norway, even compared with data from 1978/1979. Use of bisphosphonate may explain up to one third of the decline in the incidence.


The aims of the present study were to report the current incidence of hip fractures in Oslo and to estimate the influence of bisphosphonates on the current incidence.


Using the electronic diagnosis registers and lists from the operating theaters of the hospitals of Oslo, all patients with ICD-10 codes S72.0 and S72.1 (hip fracture) in 2007 were identified. Medical records of all identified patients were reviewed to verify the diagnosis. Age- and gender-specific annual incidence rates were calculated using the population of Oslo on January 1, 2007 as the population at risk. Data on the use of bisphosphonates were obtained from official registers.


A total number of 1,005 hip fractures, 712 (71%) in women, were included. The age-adjusted fracture rates per 10,000 for the age group >50 years were 82.0 for women and 39.1 for men in 2007, compared with 110.8 and 41.4 in 1996/1997, 116.5 and 42.9 in 1988/1989, and 97.5 and 34.5 in 1978/1979, respectively. It was estimated that the use of bisphosphonates may explain up to 13% of the decline in incidence in women aged 60–69 years and up to 34% in women aged 70–79 years.


The incidence of hip fractures in women in Oslo has decreased significantly during the last decade and is now at a lower level than in 1978/1979. This reduction was not evident in men. The incidence of hip fractures in Oslo is, however, still the highest in the world.


Bisphosphonates Epidemiology Hip fracture Incidence Osteoporosis 



The authors thank the four somatic emergency hospitals serving the population of Oslo for help and assistance during the data collection. The project was funded by the South-Eastern Norway Regional Health Authority.

Conflicts of interest



  1. 1.
    Osnes EK, Lofthus CM, Meyer HE, Falch JA, Nordsletten L, Cappelen I, Kristiansen IS (2004) Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 15:567–574PubMedCrossRefGoogle Scholar
  2. 2.
    Lu-Yao GL, Keller RB, Littenberg B, Wennberg JE (1994) Outcomes after displaced fractures of the femoral neck. A meta-analysis of one hundred and six published reports. J Bone Joint Surg Am 76:15–25PubMedGoogle Scholar
  3. 3.
    Shi N, Foley K, Lenhart G, Badamgarav E (2009) Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 45:1084–1090PubMedCrossRefGoogle Scholar
  4. 4.
    Lofthus CM, Osnes EK, Falch JA, Kaastad TS, Kristiansen IS, Nordsletten L, Stensvold I, Meyer HE (2001) Epidemiology of hip fractures in Oslo, Norway. Bone 29:413–418PubMedCrossRefGoogle Scholar
  5. 5.
    Leslie WD, O’Donnell S, Jean S, Lagace C, Walsh P, Bancej C, Morin S, Hanley DA, Papaioannou A, for the Osteoporosis Surveillance Expert Working Group (2009) Trends in hip fracture rates in Canada. JAMA 302:883–889PubMedCrossRefGoogle Scholar
  6. 6.
    Ahlborg HG, Rosengren BE, Jarvinen TL, Rogmark C, Nilsson JA, Sernbo I, Karlsson MK (2010) Prevalence of osteoporosis and incidence of hip fracture in women—secular trends over 30 years. BMC Musculoskelet Disord 11:48PubMedCrossRefGoogle Scholar
  7. 7.
    Statistics Norway; available at 2009-02-10
  8. 8.
    Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRefGoogle Scholar
  9. 9.
    Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155.Google Scholar
  10. 10.
    Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:3–13CrossRefGoogle Scholar
  11. 11.
    Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004–2007—a nationwide register study in Norway. Eur J Clin Pharmacol 66:299–306PubMedCrossRefGoogle Scholar
  12. 12.
    Falch JA, Ilebekk A, Slungaard U (1985) Epidemiology of hip fractures in Norway. Acta Orthop Scand 56:12–16PubMedCrossRefGoogle Scholar
  13. 13.
    Falch JA, Kaastad TS, Bohler G, Espeland J, Sundsvold OJ (1993) Secular increase and geographical differences in hip fracture incidence in Norway. Bone 14:643–645PubMedCrossRefGoogle Scholar
  14. 14.
    Wholesale based drug statistics; available at 2010-08-10.
  15. 15.
    Norwegian Prescription Database; available at 2010-08-10.
  16. 16.
    Falch JA (1996) Meyer HE [Bone mineral density measured by dual X-ray absorptiometry. A reference material from Oslo]. Tidsskr Nor Laegeforen 116:2299–2302PubMedGoogle Scholar
  17. 17.
    Kanis JA, Johnell O, Oden A, Jonsson B, De LC, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585–590PubMedCrossRefGoogle Scholar
  18. 18.
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124PubMedCrossRefGoogle Scholar
  19. 19.
    Armitage P, Berry G (1994) Statistical methods in medical research.Google Scholar
  20. 20.
    Icks A, Haastert B, Wildner M, Becker C, Meyer G (2008) Hip fracture incidence in Germany: analysis of the national hospital discharge registry 2004. Dtsch Med Wochenschr 133:125–128PubMedCrossRefGoogle Scholar
  21. 21.
    Holt G, Smith R, Duncan K, Hutchison JD, Gregori A (2008) Gender differences in epidemiology and outcome after hip fracture: evidence from the Scottish Hip Fracture Audit. J Bone Joint Surg Br 90:480–483PubMedCrossRefGoogle Scholar
  22. 22.
    Moayyeri A, Soltani A, Larijani B, Naghavi M, Alaeddini F, Abolhassani F (2006) Epidemiology of hip fracture in Iran: results from the Iranian multicenter study on accidental injuries. Osteoporos Int 17:1252–1257PubMedCrossRefGoogle Scholar
  23. 23.
    El MA, Koumba BA, Jroundi I, Achemlal L, Bezza A, Tazi MA (2005) Epidemiology of hip fractures in 2002 in Rabat, Morocco. Osteoporos Int 16:597–602CrossRefGoogle Scholar
  24. 24.
    Hagino H, Katagiri H, Okano T, Yamamoto K, Teshima R (2005) Increasing incidence of hip fracture in Tottori Prefecture, Japan: trend from 1986 to 2001. Osteoporos Int 16:1963–1968PubMedCrossRefGoogle Scholar
  25. 25.
    Soveid M, Serati AR, Masoompoor M (2005) Incidence of hip fracture in Shiraz, Iran. Osteoporos Int 16:1412–1416PubMedCrossRefGoogle Scholar
  26. 26.
    de Pina MF, Alves SM, Barbosa M, Barros H (2008) Hip fractures cluster in space: an epidemiological analysis in Portugal. Osteoporos Int 19:1797–1804PubMedCrossRefGoogle Scholar
  27. 27.
    Chie WC, Yang RS, Liu JP, Tsai KS (2004) High incidence rate of hip fracture in Taiwan: estimated from a nationwide health insurance database. Osteoporos Int 15:998–1002PubMedCrossRefGoogle Scholar
  28. 28.
    Abolhassani F, Moayyeri A, Naghavi M, Soltani A, Larijani B, Shalmani HT (2006) Incidence and characteristics of falls leading to hip fracture in Iranian population. Bone 39:408–413PubMedCrossRefGoogle Scholar
  29. 29.
    Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Jarvinen M, Vuori I (2000) Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 343:1506–1513PubMedCrossRefGoogle Scholar
  30. 30.
    Gale CR, Martyn CN, Kellingray S, Eastell R, Cooper C (2001) Intrauterine programming of adult body composition. J Clin Endocrinol Metab 86:267–272PubMedCrossRefGoogle Scholar
  31. 31.
    Droyvold WB, Nilsen TI, Kruger O, Holmen TL, Krokstad S, Midthjell K, Holmen J (2006) Change in height, weight and body mass index: longitudinal data from the HUNT study in Norway. Int J Obes (Lond) 30:935–939CrossRefGoogle Scholar
  32. 32.
    Statistics Norway, NSD. National health survey 2008. 2009; NSD1327.Google Scholar
  33. 33.
    Statistics Norway, NSD. National health survey 1998. 2009; NSD0415.Google Scholar
  34. 34.
    Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S (1998) Hormone replacement therapy and risk of hip fracture: population based case–control study. BMJ 316:1858–1863PubMedCrossRefGoogle Scholar
  35. 35.
    Meyer HE, Lofthus CM, Sogaard AJ, Falch JA (2008) Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. Osteoporos Int 5:827–830Google Scholar
  36. 36.
    Lofthus CM, Frihagen F, Meyer HE, Nordsletten L, Melhuus K, Falch JA (2008) Epidemiology of distal forearm fractures in Oslo, Norway. Osteoporos Int 19:781–786PubMedCrossRefGoogle Scholar
  37. 37.
    Cheng SY, Levy AR, Lefaivre KA, Guy P, Kuramoto L, Sobolev B (2011) Geographic trends in incidence of hip fractures: a comprehensive literature review. Osteoporos Int 10:2575–2586CrossRefGoogle Scholar
  38. 38.
    Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573–1579PubMedCrossRefGoogle Scholar
  39. 39.
    Lofthus CM, Cappelen I, Osnes EK, Falch JA, Kristiansen IS, Medhus AW, Nordsletten L, Meyer HE (2005) Local and national electronic databases in Norway demonstrate a varying degree of validity. J Clin Epidemiol 58:280–285PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  • R. Ø. Støen
    • 1
    Email author
  • L. Nordsletten
    • 1
    • 3
  • H. E. Meyer
    • 4
    • 5
  • J. F. Frihagen
    • 1
  • J. A. Falch
    • 4
  • C. M. Lofthus
    • 2
    • 3
  1. 1.Department of OrthopaedicsOslo University Hospital, UllevålOsloNorway
  2. 2.Department of EndocrinologyOslo University Hospital, AkerOsloNorway
  3. 3.University of OsloOsloNorway
  4. 4.Division of Epidemiology, Department of Chronic DiseasesNorwegian Institute of Public HealthOsloNorway
  5. 5.Department of Community Medicine, Institute of Health and SocietyUniversity of OsloOsloNorway

Personalised recommendations